Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Pharmacokinetic Limitations to Overcome and Enable K777 as a Potential Drug against Chagas Disease

Author(s): Marianny De Souza, Daniel Calazans Medeiros, Ricardo Olimpio de Moura and Igor José dos Santos Nascimento*

Volume 29, Issue 30, 2023

Published on: 11 October, 2023

Page: [2359 - 2360] Pages: 2

DOI: 10.2174/0113816128267517231010061552

Price: $65

conference banner
Next »
[1]
dos Santos Nascimento IJ, de Aquino TM, da Silva-Júnior EF. Cruzain and rhodesain inhibitors: Last decade of advances in seeking for new compounds against American and African trypanosomiases. Curr Top Med Chem 2021; 21(21): 1871-99.
[http://dx.doi.org/10.2174/18734294MTE10MTEoz] [PMID: 33797369]
[2]
Mellott DM, Tseng CT, Drelich A, et al. A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells. ACS Chem Biol 2021; 16(4): 642-50.
[http://dx.doi.org/10.1021/acschembio.0c00875] [PMID: 33787221]
[3]
Judice WAS, Ferraz LS, Lopes RM, et al. Cysteine proteases as potential targets for anti-trypanosomatid drug discovery. Bioorg Med Chem 2021; 46: 116365.
[http://dx.doi.org/10.1016/j.bmc.2021.116365] [PMID: 34419821]
[4]
Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures Chagas’ disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 2007; 51(11): 3932-9.
[http://dx.doi.org/10.1128/AAC.00436-07] [PMID: 17698625]
[5]
Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49(12): 5160-1.
[http://dx.doi.org/10.1128/AAC.49.12.5160-5161.2005] [PMID: 16304193]
[6]
McKerrow J, Engel JC, Caffrey CR. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 1999; 7(4): 639-44.
[http://dx.doi.org/10.1016/S0968-0896(99)00008-5] [PMID: 10353643]
[7]
Field MC, Horn D, Fairlamb AH, et al. Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat Rev Microbiol 2017; 15(4): 217-31.
[http://dx.doi.org/10.1038/nrmicro.2016.193] [PMID: 28239154]
[8]
Jacobsen W, Christians U, Benet LZ. In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos 2000; 28(11): 1343-51.
[PMID: 11038163]
[9]
Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther 2014; 96(3): 340-8.
[http://dx.doi.org/10.1038/clpt.2014.129] [PMID: 24926778]
[10]
Kaur P, Chamberlin AR, Poulos TL, Sevrioukova IF. Structure-based inhibitor design for evaluation of a CYP3A4 pharmacophore model. J Med Chem 2016; 59(9): 4210-20.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01146] [PMID: 26371436]
[11]
Halford B. The path to paxlovid. ACS Cent Sci 2022; 8(4): 405-7.
[http://dx.doi.org/10.1021/acscentsci.2c00369] [PMID: 35505871]
[12]
Engel JC, García CT, Hsieh I, Doyle PS, McKerrow JH. Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi. J Cell Sci 2000; 113(8): 1345-54.
[http://dx.doi.org/10.1242/jcs.113.8.1345] [PMID: 10725218]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy